Previous 10 | Next 10 |
2023-05-15 09:19:47 ET BriaCell ( NASDAQ: BCTX ) announced that Prevail Partners had agreed to purchase 463K of its common shares at $8.63 per share, resulting in $4M in gross proceeds, and revealed that Prevail InfoWorks had also been chosen as the CRO for their upcoming pivo...
Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell’...
15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. The Bria-IMT ™ combination regimen...
2023-04-10 14:26:22 ET "Naked Short Selling: What It Is and How It Works." For further details see: SMX Security Matters to probe suspected illegal trading, shares soar
2023-03-30 10:20:27 ET BriaCell Therapeutics ( NASDAQ: BCTX ) is planning a reorganization under which it intends to spin-out certain pre-clinical assets to an unlisted corporation to own the SpinCo Assets (SpinCo). The SpinCo Assets include Bria-TILsRx and PKCδ ...
SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOU...
2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has ...
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. Remains well tolerated with no dose limiting toxicities. Primary endpoint in pending pivotal trial will be survival, as agreed by the FDA. 9 additional patients have been s...
Summary BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted novel immuno-therapies to fight breast and prostate cancer. The FDA has agreed on the registration study design which will enroll advanced metastatic breast cancer patients for whom no...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
BriaCell Therapeutics Corp. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...